San Diego-based Pleno has initiated an early-access program for its Raptor platform, which leverages 'hypercoding' technology with circularizable probes to simultaneously target tens of thousands of biomarkers across DNA, RNA, methylation, and proteins. The program, involving partners like Slopes Bio, aims to validate the platform’s high-throughput genomics capabilities and cost-effective performance ahead of its anticipated commercial launch in 2026 or 2027.